Rexahn Pharmaceuticals Inc RNN:NYSE MKT LLC (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
0.76 0.0023   0.30% 1,023,7681.7M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/8/2014

Latest News Headlines for Rexahn Pharmaceuticals Inc

Rexahn Pharmaceuticals to Present at 13th Annual BIO Investor Forum

Rexahn Pharmaceuticals to Present at 13th Annual BIO Investor Forum ROCKVILLE, Md., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present at the 13(th) Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13(th) Annual BIO Investor Forum features leading private and emerging public companies. The presentation will be on Tuesday, October 7 at 10:30 am PDT. The presentation will be webcast live. To access the webcast, please visit http://www.veracast.com/webcasts/bio/investorforum2014/36105151112.cfm. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company's pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company's drug candidate, Archexin is an anticancer Akt inhibitor.

http://www.rexahn.com

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open0.769
Previous Close0.76
Day High--
Day Low--
52 Week High1/13/2014 | 1.85
52 Week Low11/7/2013 | 0.37
% Off 52 Week High(58.92)%
% Off 52 Week Low105.41%
Beta (5 Yr)1.05
Volatility Avg10/8/2014 | 106.85
10-Day Avg. Volume1,664,152
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2014 | (0.12)
P/E Ratio6/30/2014 | --
Market CapMicro Cap | 135M
Shares Outstanding178.25M
Float155.4M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short5.30M
Short Ratio3.6
Short % of Float3.41%
As of 9/15/2014

Peers Information HelpRNN Rexahn Pharmaceuticals Inc vs. Peers

Peers 
RNN
Rexahn Pharmaceuticals Inc
49.02%
Pfizer Inc.
-4.08%
Eli Lilly and Co
27.92%
Bristol-Myers Squibb Co
-5.53%
Keryx Biopharmaceuticals
27.34%
RNN
Rexahn Pharmaceuticals Inc
0.00%
Pfizer Inc.
3.54%
Eli Lilly and Co
3.00%
Bristol-Myers Squibb Co
2.87%
Keryx Biopharmaceuticals
--
RNN
Rexahn Pharmaceuticals Inc
0.30%
Pfizer Inc.
2.05%
Eli Lilly and Co
1.59%
Bristol-Myers Squibb Co
0.88%
Keryx Biopharmaceuticals
5.17%
Compare these stocks